Oral Proteins & Peptides Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Application, By Region & Competition, 2020-2030F

Description

The Global Oral Proteins & Peptides Market was valued at USD 1.33 billion in 2024 and is expected to experience significant growth during the forecast period, with a compound annual growth rate (CAGR) of 9.42% through 2030. This market is rapidly expanding within the pharmaceutical and biotechnology sectors. Oral proteins and peptides are bioactive molecules that can be taken orally, typically in the form of tablets, capsules, or liquids, providing an alternative to injectable therapies. This method of administration offers multiple advantages, including improved patient compliance, reduced discomfort, and lower healthcare costs.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.33 Billion
Market Size 2030	USD 2.26 Billion
CAGR 2025-2030	9.42%
Fastest Growing Segment	Plecanatide
Largest Market	North America

Key Market Drivers:

Increasing Prevalence of Chronic Diseases

The rising prevalence of chronic diseases is a key factor driving the growth of the oral proteins and peptides market. As the global population ages and lifestyles become more sedentary and unhealthy, the incidence of chronic diseases is increasing. This leads to a larger patient pool that could benefit from oral protein and peptide treatments. According to the World Health Organization, noncommunicable diseases (NCDs) were responsible for 43 million deaths, accounting for 75% of all global deaths unrelated to pandemics. Cardiovascular diseases were the leading cause with 19 million deaths, followed by cancers (10 million), chronic respiratory diseases (4 million), and diabetes (over 2 million). Notably, low- and middle-income countries accounted for 73% of these NCD-related deaths.

Patients with chronic conditions are increasingly seeking convenient treatment options. Many require long-term or lifelong therapies, and traditional methods such as injections or infusions can be burdensome. Oral proteins and peptides provide a more patient-friendly alternative, as they can be taken in the form of a pill or liquid, eliminating the need for painful, frequent injections. Additionally, non-adherence to prescribed treatments is a significant challenge in managing chronic diseases. Oral formulations help address this issue by increasing patient compliance, as treatments that are easier to administer and less intrusive encourage better adherence and lead to improved health outcomes.

Key Market Challenges:

Stability and Bioavailability

A major challenge in the oral administration of proteins and peptides is their susceptibility to degradation in the harsh environment of the gastrointestinal tract. Ensuring their stability and maintaining adequate bioavailability remains a complex issue that requires advanced formulation technologies.

Key Market Trends:

Advancements in Nanotechnology and Drug Delivery Systems

Nanotechnology is transforming drug delivery in the oral proteins and peptides market. Nanoparticles and nanocarriers are being developed to encapsulate and protect these sensitive molecules, enabling more precise delivery and enhanced bioavailability. These innovations are expected to expand the range of treatable diseases and improve therapeutic outcomes.

Key Market Players:

AbbVie Inc.
Merck & Co., Inc.
Pfizer Inc.
Novo Nordisk A/S
Hoffmann-La Roche Inc.
Sanofi S.A.
AstraZeneca PLC
Bristol-Myers Squibb Co.
Tarsa Therapeutics Inc.
Novartis AG

Report Scope:

This report segments the Global Oral Proteins & Peptides Market into the following categories, with detailed insights into each:

By Drug Type:

Calcitonin
Insulin
Linaclotide
Octreotide
Plecanatide

By Application:

Bone Diseases
Diabetes
Gastric & Digestive Disorders
Hormonal Disorders

By Region:

North America: United States, Canada, Mexico
Europe: Germany, United Kingdom, France, Italy, Spain
Asia-Pacific: China, Japan, India, Australia, South Korea
South America: Brazil, Argentina, Colombia
Middle East & Africa: South Africa, Saudi Arabia, UAE, Kuwait

Competitive Landscape and Company Profiles:

This section offers an in-depth analysis of the major players in the Global Oral Proteins & Peptides Market.

Available Customizations:

TechSci Research provides customized reports tailored to specific market needs. The following customization options are available:

Detailed analysis and profiling of up to five additional market players.

Product Code: 18807

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Proteins & Peptides Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
- 5.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Product Market Map
- 5.3.1. By Drug Type
- 5.3.2. By Application
- 5.3.3. By Region

6. North America Oral Proteins & Peptides Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
- 6.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Oral Proteins & Peptides Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Type
    - 6.3.1.2.2. By Application
- 6.3.2. Canada Oral Proteins & Peptides Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Type
    - 6.3.2.2.2. By Application
- 6.3.3. Mexico Oral Proteins & Peptides Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Type
    - 6.3.3.2.2. By Application

7. Europe Oral Proteins & Peptides Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
- 7.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Oral Proteins & Peptides Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Type
    - 7.3.1.2.2. By Application
- 7.3.2. United Kingdom Oral Proteins & Peptides Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Type
    - 7.3.2.2.2. By Application
- 7.3.3. France Oral Proteins & Peptides Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Type
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Oral Proteins & Peptides Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Type
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Oral Proteins & Peptides Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Type
    - 7.3.5.2.2. By Application

8. Asia-Pacific Oral Proteins & Peptides Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
- 8.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Oral Proteins & Peptides Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Type
    - 8.3.1.2.2. By Application
- 8.3.2. Japan Oral Proteins & Peptides Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Type
    - 8.3.2.2.2. By Application
- 8.3.3. India Oral Proteins & Peptides Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Type
    - 8.3.3.2.2. By Application
- 8.3.4. Australia Oral Proteins & Peptides Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Type
    - 8.3.4.2.2. By Application
- 8.3.5. South Korea Oral Proteins & Peptides Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Type
    - 8.3.5.2.2. By Application

9. South America Oral Proteins & Peptides Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
- 9.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Oral Proteins & Peptides Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Type
    - 9.3.1.2.2. By Application
- 9.3.2. Argentina Oral Proteins & Peptides Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Type
    - 9.3.2.2.2. By Application
- 9.3.3. Colombia Oral Proteins & Peptides Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Type
    - 9.3.3.2.2. By Application

10. Middle East and Africa Oral Proteins & Peptides Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
- 10.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Oral Proteins & Peptides Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Type
    - 10.3.1.2.2. By Application
- 10.3.2. Saudi Arabia Oral Proteins & Peptides Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Type
    - 10.3.2.2.2. By Application
- 10.3.3. UAE Oral Proteins & Peptides Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Type
    - 10.3.3.2.2. By Application
- 10.3.4. Kuwait Oral Proteins & Peptides Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Drug Type
    - 10.3.4.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. AbbVie Inc.
14.2. Merck & Co Inc
14.3. Pfizer Inc
14.4. Novo Nordisk A/S
14.5. Hoffmann-La Roche Inc
14.6. Sanofi SA
14.7. AstraZeneca PLC
14.8. Bristol-Myers Squibb Co
14.9. Tarsa Therapeutics Inc
14.10.Novartis AG